Comparative Pharmacology
Head-to-head clinical analysis: K 8 versus KLOROMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K 8 versus KLOROMIN.
K+8 vs KLOROMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replenishment; corrects hypokalemia by increasing extracellular potassium concentration, restoring membrane potential and cardiac conduction.
KLOROMIN is a potassium-sparing diuretic that acts by antagonizing aldosterone in the distal renal tubules, inhibiting sodium reabsorption and potassium excretion.
40-80 mEq intravenously per day, infusion rate not exceeding 10 mEq/hour; or 20-40 mEq orally 2-4 times daily.
1 g IV every 6 hours; infuse over 30 minutes.
None Documented
None Documented
Terminal elimination half-life ~2-4 hours (shorter with valproate coadministration, prolonged with renal impairment).
Terminal elimination half-life is 8-12 hours in adults with normal renal function; extends to 20-30 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 50 hours in severe impairment (CrCl <30 mL/min).
Primarily renal: >90% excreted unchanged by kidneys. Minor fecal (<5%) and negligible biliary elimination.
Primarily renal (60-70% as unchanged drug, 10-20% as glucuronide conjugate), biliary/fecal (10-15% as metabolites).
Category C
Category C
Potassium Supplement
Potassium Supplement